GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Spectrum Pharmaceuticals, Inc. (SPPI) [hlAlert]

Rating:
Buy SPPI
up 28.03 %

Spectrum Pharmaceuticals, Inc. (SPPI) rated Buy with price target $10 by Morgan Joseph

Posted on: Tuesday,  Dec 7, 2010  9:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) on 12/07/2010, when the stock price was $5.85. Since
then, Spectrum Pharmaceuticals, Inc. has gained 28.03% as of 12/04/2015's recent price of $7.49.
If you would have followed this Morgan Joseph's recommendation on SPPI, you would have gained 28.03% of your investment in 1823 days.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company?s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/7/2010 9:25 AM Buy
None
5.85 10.00
as of 12/31/2010
1 Week up  1.76 %
1 Month up  42.92 %
3 Months up  52.51 %
1 YTD up  8.71 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/12/2010 1:44 PM Buy
None
5.10 8.00
9/8/2009 8:25 AM Hold
None
7.95
9/9/2008 8:25 AM Buy
None
1.67 5.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy